NCT01615601View on ClinicalTrials.gov

An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients

CompletedOBSERVATIONAL
Enrollment

77

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Human Immunodeficiency Virus (HIV)
Interventions
DRUG

darunavir (PREZISTA)

Form = tablet, route = oral, Units = mg, number = 800 administered once daily

DRUG

etravirine (INTELENCE)

Form = tablet, route = oral, Unit = mg, number = 200, administered twice daily

DRUG

ritonavir

Form = tablet/capsule, route = oral, Units = mg, number = 100 administered once daily

DRUG

Other antiretroviral medications

Given as per Canadian Product Monograph

Trial Locations (1)

Unknown

Vancouver

All Listed Sponsors
lead

Janssen Inc.

INDUSTRY

NCT01615601 - An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients | Biotech Hunter | Biotech Hunter